Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
Gamble, LD
Purgato, S
Murray, J
Xiao, L
Yu, DMT
Hanssen, KM
Giorgi, FM
Carter, DR
Gifford, AJ
Valli, E
Milazzo, G
Kamili, A
Mayoh, C
Liu, B
Eden, G
Sarraf, S
Allan, S
Giacomo, SD
Flemming, CL
Russell, AJ
Cheung, BB
Oberthuer, A
London, WB
Fischer, M
Trahair, TN
Fletcher, JI
Marshall, GM
Ziegler, DS
Hogarty, MD
Burns, MR
Perini, G
Norris, MD
Haber, M
- Publication Type:
- Journal Article
- Citation:
- Science Translational Medicine, 2019, 11 (477)
- Issue Date:
- 2019-01-30
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.pdf | Published Version | 1.48 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Gamble, LD | en_US |
dc.contributor.author | Purgato, S | en_US |
dc.contributor.author | Murray, J | en_US |
dc.contributor.author | Xiao, L | en_US |
dc.contributor.author | Yu, DMT | en_US |
dc.contributor.author | Hanssen, KM | en_US |
dc.contributor.author | Giorgi, FM | en_US |
dc.contributor.author | Carter, DR | en_US |
dc.contributor.author | Gifford, AJ | en_US |
dc.contributor.author | Valli, E | en_US |
dc.contributor.author | Milazzo, G | en_US |
dc.contributor.author | Kamili, A | en_US |
dc.contributor.author | Mayoh, C | en_US |
dc.contributor.author | Liu, B | en_US |
dc.contributor.author | Eden, G | en_US |
dc.contributor.author | Sarraf, S | en_US |
dc.contributor.author | Allan, S | en_US |
dc.contributor.author | Giacomo, SD | en_US |
dc.contributor.author | Flemming, CL | en_US |
dc.contributor.author | Russell, AJ | en_US |
dc.contributor.author | Cheung, BB | en_US |
dc.contributor.author | Oberthuer, A | en_US |
dc.contributor.author | London, WB | en_US |
dc.contributor.author | Fischer, M | en_US |
dc.contributor.author | Trahair, TN | en_US |
dc.contributor.author | Fletcher, JI | en_US |
dc.contributor.author | Marshall, GM | en_US |
dc.contributor.author | Ziegler, DS | en_US |
dc.contributor.author | Hogarty, MD | en_US |
dc.contributor.author | Burns, MR | en_US |
dc.contributor.author | Perini, G | en_US |
dc.contributor.author | Norris, MD | en_US |
dc.contributor.author | Haber, M | en_US |
dc.date.available | 2019-01-08 | en_US |
dc.date.issued | 2019-01-30 | en_US |
dc.identifier.citation | Science Translational Medicine, 2019, 11 (477) | en_US |
dc.identifier.issn | 1946-6234 | en_US |
dc.identifier.uri | http://hdl.handle.net/10453/135528 | |
dc.description.abstract | Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Amplification of the MYCN oncogene is associated with an aggressive phenotype and poor outcome in childhood neuroblastoma. Polyamines are highly regulated essential cations that are frequently elevated in cancer cells, and the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase 1 (ODC1), is a direct transcriptional target of MYCN. Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment. In this study, we identified solute carrier family 3 member 2 (SLC3A2) as the key transporter involved in polyamine uptake in neuroblastoma. Knockdown of SLC3A2 in neuroblastoma cells reduced the uptake of the radiolabeled polyamine spermidine, and DFMO treatment increased SLC3A2 protein. In addition, MYCN directly increased polyamine synthesis and promoted neuroblastoma cell proliferation by regulating SLC3A2 and other regulatory components of the polyamine pathway. Inhibiting polyamine uptake with the small-molecule drug AMXT 1501, in combination with DFMO, prevented or delayed tumor development in neuroblastoma-prone mice and extended survival in rodent models of established tumors. Our findings suggest that combining AMXT 1501 and DFMO with standard chemotherapy might be an effective strategy for treating neuroblastoma. | en_US |
dc.relation.ispartof | Science Translational Medicine | en_US |
dc.relation.isbasedon | 10.1126/scitranslmed.aau1099 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject.mesh | Cell Line, Tumor | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Neuroblastoma | en_US |
dc.subject.mesh | Disease Models, Animal | en_US |
dc.subject.mesh | Disease Progression | en_US |
dc.subject.mesh | Polyamines | en_US |
dc.subject.mesh | Membrane Transport Proteins | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.subject.mesh | Multivariate Analysis | en_US |
dc.subject.mesh | Proportional Hazards Models | en_US |
dc.subject.mesh | Survival Analysis | en_US |
dc.subject.mesh | Cohort Studies | en_US |
dc.subject.mesh | Gene Expression Regulation | en_US |
dc.subject.mesh | Gene Amplification | en_US |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | en_US |
dc.subject.mesh | Biosynthetic Pathways | en_US |
dc.subject.mesh | N-Myc Proto-Oncogene Protein | en_US |
dc.title | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma | en_US |
dc.type | Journal Article | |
utslib.citation.volume | 477 | en_US |
utslib.citation.volume | 11 | en_US |
utslib.for | 0604 Genetics | en_US |
utslib.for | 1112 Oncology and Carcinogenesis | en_US |
utslib.for | 1114 Paediatrics and Reproductive Medicine | en_US |
utslib.for | 06 Biological Sciences | en_US |
utslib.for | 11 Medical and Health Sciences | en_US |
pubs.embargo.period | Not known | en_US |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
utslib.copyright.status | closed_access | * |
pubs.issue | 477 | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 11 | en_US |
Abstract:
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Amplification of the MYCN oncogene is associated with an aggressive phenotype and poor outcome in childhood neuroblastoma. Polyamines are highly regulated essential cations that are frequently elevated in cancer cells, and the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase 1 (ODC1), is a direct transcriptional target of MYCN. Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment. In this study, we identified solute carrier family 3 member 2 (SLC3A2) as the key transporter involved in polyamine uptake in neuroblastoma. Knockdown of SLC3A2 in neuroblastoma cells reduced the uptake of the radiolabeled polyamine spermidine, and DFMO treatment increased SLC3A2 protein. In addition, MYCN directly increased polyamine synthesis and promoted neuroblastoma cell proliferation by regulating SLC3A2 and other regulatory components of the polyamine pathway. Inhibiting polyamine uptake with the small-molecule drug AMXT 1501, in combination with DFMO, prevented or delayed tumor development in neuroblastoma-prone mice and extended survival in rodent models of established tumors. Our findings suggest that combining AMXT 1501 and DFMO with standard chemotherapy might be an effective strategy for treating neuroblastoma.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph